fresenius-buys-daburs-indian-oncology-business

Fresenius buys Dabur's Indian oncology business

Fresenius is to acquire India's Dabur Pharma for $219 million giving it access to a portfolio of cancer treatment drugs and a supply of raw materials.
IndiaÆs Dabur Group has sold its 73.3% controlling interest in Dabur Pharma to Fresenius Kabi for Ç139 million $219 million.

Dabur Pharma is the residual pharmaceuticals business of Dabur Group. The largest business of the group, which is owned by the Delhi-based Burman family, is Dabur India. Dabur India has been operating since 1884 and is today a $250 million company focused on healthcare, personal care and food products. Its brands are especially well respected in the ayurvedic category, the Indian system of medicine based on natural and holistic healing. Analysts comment that the move by the Burmans to sell Dabur Pharma is intended to free resources to enhance focus on Dabur India.

Dabur...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222